linjc16/ctgov huggingface dataset:
Different Insulin Regimens and Postprandial Coagulation Activation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study in patients with type 2 diabetes was to investigate the acute effect of postprandial blood glucose levels modified by two different insulin treatment regimens on coagulation activation, inflammation and endothelial cell function. The investigators hypothesized that the rapid-acting insulin analogue aspart has a beneficial postprandial effect on coagulation, endothelial dysfunction and inflammation compared with the intermediate-acting insulin NPH due to its ability to lower postprandial glycaemia.

Official Title
-----------------
Effects of Standardised Meals on Postprandial Coagulation Activation in Patients With Type 2 Diabetes Treated With Two Different Insulin Regimens

Conditions
-----------------
Type 2 Diabetes, Cardiovascular Risk, Hemostasis, Inflammation, Endothelial Function

Intervention / Treatment
-----------------
* Dietary Supplement: Standardised meals


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 30-75 years BMI > 25 kg/m2 type 2 diabetes for more than 4 years pharmacological anti-diabetic treatment with insulin NPH at bedtime or insulin aspart at meals for more than 24 months metformin with stable dose >1000 mg/d for more than 12 weeks acetylsalicylic acid (75 mg/d) for more than 2 weeks no other anti-diabetic treatment 3 month previously HbA1c<8.5% at recruitment. Exclusion Criteria: creatinine > 120 µmol/l ALAT /ASAT > 2.5 x upper reference limit use of anticoagulants within 1 month previously any changes in dose of statins within 1 month previously night work present or planned pregnancy mental sickness or alcohol abuse clinically relevant major organ or systemic illness uncontrolled hypertension >180/110 mmHg steroid treatment known or suspected allergy to trial medications.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Insulin aspart<br> | Dietary Supplement: Standardised meals<br> <br> |
| Experimental: NPH insulin<br> | Dietary Supplement: Standardised meals<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prothrombin fragment 1+2 |  | 7.40; 9.30; 11.30; 13.30; 15.30 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| C-reactive protein |  | 7.40; 9.30; 11.30; 13.30; 15.30 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hyperglycaemia, Postprandial, Type 2 diabetes, Cardiovascular risk markers
Effects of a Hydroxyapatite-based Mouth Gel on Calcium Content of Plaque

Study Overview
=================
Brief Summary
-----------------
The aim of this pilot study is to analyze if a hydroxyapatite-containing mouth gel has an influence on the calcium content of plaque.

Detailed Description
-----------------
>= 20 subjects (7-11 years) use the hydroxyapatite-containing mouth gel for 3 days (3x per day); without using any other oral care product at this time. A dentist applies the gel on all teeth. At baseline and after 3 days plaque will be collected from buccal and labial surfaces (except surfaces with tartar). A split-mouth concept will be used: Subjects in group A: Baseline plaque collection: quadrant 1 and 4 Plaque collection after 3 days: quadrant 2 and 3 Subjects in group B: Baseline plaque collection: quadrant 2 and 3 Plaque collection after 3 days: quadrant 1 and 4 (The time between last application of the gel and plaque collection will be 1 h) The plaque will be dried and afterwards the calcium content of the plaque will be quantitively analyzed by atomic absorption spectroscopy (AAS). For all subjects: Calcium contents of plaque at baseline and after 3 days application will be compared by statistical methods.

Official Title
-----------------
Effects of a Hydroxyapatite-based Mouth Gel on Calcium Content of Plaque

Conditions
-----------------
Dental Caries

Intervention / Treatment
-----------------
* Other: Mouth gel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Girls and boys (7-11 years) Visible plaque >= 4 teeth Good overall health Exclusion Criteria: Allergic to one or more ingredients of the mouth gel Medication intake (e.g. antibiotics) Any other reason that, in the opinion of the investigator, disqualifies the subject from participating in the study

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mouth gel<br>A mouth gel with hydroxyapatite | Other: Mouth gel<br>* Stop using the mouth gel<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Calcium content of plaque | Analysis by atomic absorption spectroscopy (AAS) | 3 days |
Transferrin Saturation Coefficient and Ferritinemia in Diagnosis of Iron Deficiency

Study Overview
=================
Brief Summary
-----------------
Transferrin saturation coefficient and ferritinemia in diagnosis of iron deficiency

Official Title
-----------------
Accordance Between Transferrin Saturation Coefficient and Ferritinemia in Diagnosis of Iron Deficiency, in Patients Hospitalised in Internal Medicine Service and 65 Years Old and More

Conditions
-----------------
Iron-deficiency, Internal Medicine, Transferrin, Ferritinemia

Intervention / Treatment
-----------------
* Diagnostic Test: biologic analysis (ferritinemia, transferrin saturation coefficient)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥ 65 years old Patient hospitalized in the internal medicine and geriatry service Patient affiliated with a social security scheme Patient signed an Informed consent Exclusion Criteria: Risk benefit balance not in favor of iron deficiency check-up Patient in palliative care

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hospitalized patients aged 65 and over<br>- Patients aged 65 and over hospitalized in the department of Internal Medicine and Geriatry | Diagnostic Test: biologic analysis (ferritinemia, transferrin saturation coefficient)<br>* Each patient will follow a blood test in order to compare between ferritinemia and transferrin saturation coefficient in iron deficiency diagnosis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Agreement between Transferrin Saturation Coefficient (TSC) and ferritinemia dosage | The overall agreement, assessed by kappa Cohen | Day one | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of iron deficiency with and without anaemia | Number of patients with iron deficiency with or without anaemia | Day one | 
| Prevalence of etiologies of iron deficiency | Number of patients for each etiology | Day one | 
| Prevalence of iron deficiency in patients with anticoagulant and platelet aggregation inhibitor |  | Day one |
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

Study Overview
=================
Brief Summary
-----------------
This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy

Detailed Description
-----------------
Primary Objective: - Evaluate tumor cell free (cf)DNA as a dynamic marker of response to immuno-oncology (IO) therapy Exploratory Objective: - Collect data on somatic mutations in cfDNA to gain insight into the biology of IO-responders and -non-responders

Official Title
-----------------
Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

Conditions
-----------------
Renal Cell Carcinoma

Intervention / Treatment
-----------------
* Other: Blood collection
* Other: Urine collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Renal Cell Carcinoma with clear cell component Stage IV Receiving IO-containing regimen Measurable disease per RECIST 1.1 Exclusion Criteria: Active cancer (exclusion criteria only for healthy patient cohort)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RCC with clear cell component<br> | Other: Blood collection<br>* 20-40 mL of blood to extract cell free DNA<br>Other: Urine collection<br>* up to 15 mL of urine to extract cell free DNA<br>|
| Healthy Volunteer (no longer recruiting)<br> | Other: Blood collection<br>* 20-40 mL of blood to extract cell free DNA<br>Other: Urine collection<br>* up to 15 mL of urine to extract cell free DNA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate tumor cfDNA as a dynamic marker of response to IO therapy | Measure of changes in the amount of tumor DNA correlated with result of routine tumor imaging studies | Up to about 2 years |
Height-based Formula for Predicting the Insertion Depth of Left-sided Double and the Role of Fiberoptic Bronchoscopy

Study Overview
=================
Brief Summary
-----------------
The use of height based formula to predict insertion depth of left-sided double lumen tube in thoracic surgery is now well established. The investigators have developed a formula to be used and published recently. The investigators verified the formula with the use of FOB. This observational study we are going to use with FOB checking if needed.

Detailed Description
-----------------
The use of a height-based formula to predict the insertion depth of left-sided double-lumen tubes in thoracic surgery is now well established. The investigators have developed a formula to be used and published recently. The investigators verified the formula with the use of FOB. This observational study will use FOB checking if needed. Our hypothesis is that DLT can insert without the use of FOB in most of the cases. That doesn't mean FOB is less required.

Official Title
-----------------
A Study on the Use of an Established Novel Height-based Formula for Predicting the Insertion Depth of Left-sided Double and the Role of Fiberoptic Bronchoscopy

Conditions
-----------------
Thoracic Anesthesia

Intervention / Treatment
-----------------
* Device: double lumen tube


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients whose procedure required placement of an LDLT Exclusion Criteria: patients with intraluminal bronchial lesions and patients with a difficult airway.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: double lumen tube|prospective cohort study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correct position of DLT with proper lung deflation without use of FOB | proper lung deflation, surgeon satisfaction | during surgical time | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thoracic anesthesia, Double lumen tube, Height based formula
The Periviable Birth Plan

Study Overview
=================
Brief Summary
-----------------
Pregnant women who are at risk of delivering their infants in the periviable period can suffer a large amount of stress and anxiety. Moreover, many women feel a loss of control over their own pregnancy. There is some evidence that more counseling and planning can help reduce maternal stress and anxiety. Patients at risk of delivering in the periviable period will be randomized to either receive standard counselling or to complete the periviable birth plan.

Official Title
-----------------
The Periviable Birth Plan: A Randomized Control Trial Evaluating an Intervention to Decrease Maternal Anxiety and Stress

Conditions
-----------------
Pregnancy, High Risk, Parturition Complication as Antepartum Condition, Anxiety, PTSD, PreTerm Birth

Intervention / Treatment
-----------------
* Behavioral: Periviable Birth Plan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old. Currently Pregnant High risk of pre-term birth in the periviable period 20+0 to 25+6 wga Exclusion Criteria: Intrauterine Fetal Demise (prior to admission) Inability to read or communicate in english

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Standard Counseling<br>Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology. | |
| Experimental: Periviable Birth Plan<br>Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology with completion of the written periviable birth plan. | Behavioral: Periviable Birth Plan<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Anxiety Scores | Patients will complete State Trait Anxiety Inventory questionnaire at the time of delivery and again at 1 year from completion of the first questionnaire. Those that do not deliver in the periviable period will complete the first questionnaire at 27 weeks gestation. | Time of Delivery and One Year | 
| Change in PTSD Scores | Patients will complete Impact of Events Scale questionnaire at the time of delivery and again at 1 year from completion of the first questionnaire. Those that do not deliver in the periviable period will complete the first questionnaire at 27 weeks gestation. | Time of Delivery and One Year |
Nephropathy in Patients With Sickle Cell Disease

Study Overview
=================
Brief Summary
-----------------
There are some diseases that give rise to diverse renal manifestations as does sickle cell disease

Detailed Description
-----------------
Such involvement adversely affects virtually all major physiological processes in the kidney, and leads to complications that are common and chronic on the one hand (such as impaired urinary concentrating ability), and those that are rare and uniformly fatal on the other (such as renal medullary carcinoma) This steady adverse renal sequelae shortens the average lifespan of patients with SCD. Proteinuria and a reduced glomerular filtration rate are risk factors associated with increased mortality among those patients with approximately 16-18% of overall mortality in this patient group is due to kidney disease. Once end stage renal disease is reached, the mortality of patients who are on haemodialysis and have SCD is increased severalfold relative to the mortality of patients who are on haemodialysis but do not have SCD. Thus,although the average lifespan of patients with SCD has increased during recent decades owing to improved management of complications outside the kidney,kidney disease contributes substantially to the still increased mortality in SCD.

Official Title
-----------------
Pattern of Sickle Cell Nephropathy in Patients With Sickle Cell Disease

Conditions
-----------------
Sickle Cell Nephropathy

Intervention / Treatment
-----------------
* Other: patient with sickle cell disease


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with sickle cell anemia attending the unit will be included in the study. Exclusion Criteria: patient with any underlaying systemic diseases other than sickle cell anaemia

Ages Eligible for Study
-----------------
Minimum Age: 5 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: patient with sickle cell disease|assess degree of renal affection in patientswith sickle cell disease attending Assuit university Children hospital by estimating some predictors of glomerular and tubular dysfunction.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sickle cell nephropathy in patient with sickle cell disease | detection of renal impairment in patients with sickle cell disease by estamating gloerular and tubular dysfunction clinicaly and laboratory | one year |
Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis

Study Overview
=================
Brief Summary
-----------------
The study is a single-center prospective cohort study of clinical application of continuously monitored data by wearable activity trackers in the patients with thyrotoxicosis. The purpose of the study is to evaluate the association between parameters of pulse rate, activity, and sleep from wearable activity trackers and the thyrotoxic status along with the treatment.

Detailed Description
-----------------
Activity trackers to be used: Fitbit Charge HR (TM) Data which ware provided by Fitbit app (TM) will be analyzed in this study.

Official Title
-----------------
Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis

Conditions
-----------------
Graves Disease, Thyrotoxicosis, Thyroiditis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing newly developed or recurrent thyrotoxicosis who are treated and followed-up in Seoul National University Bundang Hospital Patients who can use wearable activity trackers and smartphone applications In case of Graves' disease, patients who will treated by anti-thyroid drugs Exclusion Criteria: Patients who have thyrotoxic periodic paralysis In case of Graves' disease, patients who will treated by radioactive iodine therapy or thyroidectomy Patients who have thyrotoxicosis due to toxic nodular disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| thyrotoxicosis<br>patients with newly detected or recurrent thyrotoxicosis | |
| control<br>euthyroid, healthy adults | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association between parameters of pulse rate, activity, and sleep from wearable activity trackers and the thyrotoxic status |  | continuous monitoring through the study period (average 3 months) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association between user-generated dietary parameters on mobile applications and the thyrotoxic status |  | continuous monitoring through the study period (average 3 months) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
wearable activity tracker, thyrotoxicosis